Literature DB >> 26105175

Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography.

Sajedeh Eftekhari1, Renee C Gaspar2, Rhonda Roberts2, Tsing-Bau Chen3, Zhizhen Zeng3, Stephanie Villarreal2, Lars Edvinsson1, Christopher A Salvatore4.   

Abstract

Functional imaging studies have revealed that certain brainstem areas are activated during migraine attacks. The neuropeptide calcitonin gene-related peptide (CGRP) is associated with activation of the trigeminovascular system and transmission of nociceptive information and plays a key role in migraine pathophysiology. Therefore, to elucidate the role of CGRP, it is critical to identify the regions within the brainstem that process CGRP signaling. In situ hybridization and immunofluorescence were performed to detect mRNA expression and define cellular localization of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), respectively. To define CGRP receptor binding sites, in vitro autoradiography was performed with [(3)H]MK-3207 (a CGRP receptor antagonist). CLR and RAMP1 mRNA and protein expression were detected in the pineal gland, medial mammillary nucleus, median eminence, infundibular stem, periaqueductal gray, area postrema, pontine raphe nucleus, gracile nucleus, spinal trigeminal nucleus, and spinal cord. RAMP1 mRNA expression was also detected in the posterior hypothalamic area, trochlear nucleus, dorsal raphe nucleus, medial lemniscus, pontine nuclei, vagus nerve, inferior olive, abducens nucleus, and motor trigeminal nucleus; protein coexpression of CLR and RAMP1 was observed in these areas via immunofluorescence. [(3)H]MK-3207 showed high binding densities concordant with mRNA and protein expression. The present study suggests that several regions in the brainstem may be involved in CGRP signaling. Interestingly, we found receptor expression and antagonist binding in some areas that are not protected by the blood-brain barrier, which suggests that drugs inhibiting CGRP signaling may not be able to penetrate the central nervous system to antagonize receptors in these brain regions.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  CGRP; CGRP receptor antagonists; CLR; RAMP1; RRID:AB_142672; RRID:AB_2238799; RRID:AB_2314535; RRID:AB_2336928; brainstem; primate

Mesh:

Substances:

Year:  2015        PMID: 26105175     DOI: 10.1002/cne.23828

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  14 in total

1.  Current understanding of trigeminal ganglion structure and function in headache.

Authors:  Karl Messlinger; Andrew F Russo
Journal:  Cephalalgia       Date:  2018-07-10       Impact factor: 6.292

2.  CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

Authors:  Lars Edvinsson
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

3.  Calcitonin receptor antibody validation and expression in the rodent brain.

Authors:  Erica R Hendrikse; Tayla A Rees; Zoe Tasma; Christelle Le Foll; Thomas A Lutz; Andrew Siow; Peter J Wookey; Christopher S Walker; Debbie L Hay
Journal:  Cephalalgia       Date:  2022-04-11       Impact factor: 6.075

4.  The CGRP receptor antagonist BIBN4096 inhibits prolonged meningeal afferent activation evoked by brief local K+ stimulation but not cortical spreading depression-induced afferent sensitization.

Authors:  Jun Zhao; Dan Levy
Journal:  Pain Rep       Date:  2017-12-05

Review 5.  The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system.

Authors:  Karl Messlinger
Journal:  J Headache Pain       Date:  2018-03-12       Impact factor: 7.277

Review 6.  The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.

Authors:  Smriti Iyengar; Michael H Ossipov; Kirk W Johnson
Journal:  Pain       Date:  2017-04       Impact factor: 7.926

Review 7.  Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

Authors:  Philip R Holland; Peter J Goadsby
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

8.  Chronic and intermittent administration of systemic nitroglycerin in the rat induces an increase in the gene expression of CGRP in central areas: potential contribution to pain processing.

Authors:  Rosaria Greco; Chiara Demartini; Anna Maria Zanaboni; Cristina Tassorelli
Journal:  J Headache Pain       Date:  2018-07-13       Impact factor: 7.277

Review 9.  Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators.

Authors:  Karl Messlinger; Louis K Balcziak; Andrew F Russo
Journal:  J Neural Transm (Vienna)       Date:  2020-02-22       Impact factor: 3.575

Review 10.  Persistent Post-Traumatic Headache and Migraine: Pre-Clinical Comparisons.

Authors:  Matilde Capi; Leda Marina Pomes; Giulia Andolina; Martina Curto; Paolo Martelletti; Luana Lionetto
Journal:  Int J Environ Res Public Health       Date:  2020-04-09       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.